株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

西部ウマ脳炎:パイプライン製品の分析

Western Equine Encephalitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321911
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
西部ウマ脳炎:パイプライン製品の分析 Western Equine Encephalitis - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 39 Pages
概要

西部ウマ脳炎は、感染した蚊によって人に伝播する疾患です。西部ウマ脳炎は、アルボウイルスである、西部ウマ脳炎ウイルスによって引き起こされます。症状は、軽症では発熱と頭痛のみ、重症ではせん妄・見当識障害・昏睡状態を伴う脳炎まで、多岐にわたっています。

当レポートでは、西部ウマ脳炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

西部ウマ脳炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Akshaya Bio Inc.
  • AlphaVax, Inc.
  • AltraVax Inc.
  • EpiVax, Inc.
  • Profectus BioSciences, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 分子タイプ別

薬剤のプロファイル

  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • Westrern Equine Encephalitis Virus Vaccine

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8890IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.

Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Western Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Western Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Western Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Western Equine Encephalitis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Western Equine Encephalitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Western Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Western Equine Encephalitis Overview
  • Therapeutics Development
    • Pipeline Products for Western Equine Encephalitis - Overview
    • Pipeline Products for Western Equine Encephalitis - Comparative Analysis
  • Western Equine Encephalitis - Therapeutics under Development by Companies
  • Western Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
  • Western Equine Encephalitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Western Equine Encephalitis - Products under Development by Companies
  • Western Equine Encephalitis - Products under Investigation by Universities/Institutes
  • Western Equine Encephalitis - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc
    • Altravax Inc
    • EpiVax Inc
    • H&P Labs Inc
    • Profectus BioSciences Inc
  • Western Equine Encephalitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Western Equine Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Westrern Equine Encephalitis Virus Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Western Equine Encephalitis - Dormant Projects
  • Western Equine Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Western Equine Encephalitis, H2 2016
  • Number of Products under Development for Western Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Western Equine Encephalitis - Pipeline by Akshaya Bio Inc, H2 2016
  • Western Equine Encephalitis - Pipeline by Altravax Inc, H2 2016
  • Western Equine Encephalitis - Pipeline by EpiVax Inc, H2 2016
  • Western Equine Encephalitis - Pipeline by H&P Labs Inc, H2 2016
  • Western Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Western Equine Encephalitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Western Equine Encephalitis, H2 2016
  • Number of Products under Development for Western Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top